Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of ... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.98 | 14.9012567325 | 33.42 | 39.9 | 33.1212 | 90825 | 36.76050231 | DR |
| 4 | 3.58 | 10.281447444 | 34.82 | 39.9 | 31.68 | 80178 | 35.9149594 | DR |
| 12 | 8.65 | 29.0756302521 | 29.75 | 57.14 | 29.3601 | 80352 | 38.24662036 | DR |
| 26 | 15.69 | 69.0885072655 | 22.71 | 57.14 | 19.61 | 62652 | 34.6305203 | DR |
| 52 | 33.67 | 711.839323467 | 4.73 | 57.14 | 4.58 | 59541 | 27.16418442 | DR |
| 156 | 33.32 | 655.905511811 | 5.08 | 57.14 | 2.76 | 48965 | 14.85655697 | DR |
| 260 | 24.05 | 167.595818815 | 14.35 | 57.14 | 1.75 | 65772 | 10.25582829 | DR |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。